Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan

HUNTSVILLE, April 02, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina” or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported that the NYSE American LLC ("NYSE American") has accepted the Company's business plan to regain compliance with the continued listing standards set forth in Sections 1003(a)(i) or 1003(a)(ii) of the NYSE American Company Guide.